Osimertinib, another promising candidate for treating patients with EFGR insertions, has been reported to be effective in suppressing EGFR e20ins in sporadic cases (Fang et al., 2019a; Piotrowska et al., 2018b), specifically for p.S768_D770dup, p.A767_V769dup, p.N771_P772insL, p.D770_N771insG, and p.A763_Y764insFQEA mutations in NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.